Drug Profile
Research programme: insulin resistance therapies - Pfizer/Sanford-Burnham Medical Research Institute
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Pfizer; Sanford-Burnham Medical Research Institute
- Developer Pfizer; Sanford Burnham Prebys Medical Discovery Institute
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Insulin resistance
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Insulin-resistance in USA
- 13 Aug 2013 Early research in Insulin resistance (in obesity and diabetes) in USA (unspecified route)